| Статус: | Unknown status |
| Фаза: | N/A |
| Начало: | 23 апреля 2022 г. |
| Окончание: | 1 апреля 2024 г. |
| Описание: | A Multicenter, Prospective, Low-interventional Clinical Study Evaluating on mobile application validation ("ProRodinki") in assessing the risk of skin malignant neoplasms |
| смотреть на ClinicalTrials.gov |
| Статус: | Recruiting |
| Фаза: | не указано |
| Начало: | 2 марта 2022 г. |
| Окончание: | 1 апреля 2025 г. |
| Описание: | Prospective non-interventional study of clinical outcomes and biomarkers in patients with stage 0-IV skin melanoma in real clinical practice |
| смотреть на ClinicalTrials.gov |
| Статус: | Recruiting |
| Фаза: | не указано |
| Начало: | 1 января 2022 г. |
| Окончание: | 1 июля 2025 г. |
| Описание: | The goal of this observational study is to learn about if new biomarkers such as gut microbiota and molecular genetics melanoma features could predict clinical radiological and pathological response to neoadjuvant monotherapy with anti-PD1 agents in patients with resectable stage IIIB-D melanoma. The main questions it aims to answer are: - radiological and pathological response rate to three doses of antiPD1 agents; - do radiological and pathological responses correlate with gut microbiota and melanoma molecular genetics features Participants will receive three doses of aPD1 monotherapy as per center routine practice and will undergo regional lymphadenectomy. Before treatment initiation patients will be asked to bring faeces probes and fill out dietary questionnaire as well as just before the surgery. After sugery adjuvant therapy will be prescribed for 12 month and patients will be followed up according to institutional routine practice for 5 years. |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | не указано |
| Начало: | 30 сентября 2021 г. |
| Окончание: | 30 сентября 2024 г. |
| Описание: | Prospective evaluation of clinical outcomes in patients with resectable or metastatic BRAF+ melanoma treated with dabrafenib and trametinib in real practice |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | N/A |
| Начало: | 1 апреля 2020 г. |
| Окончание: | 1 ноября 2023 г. |
| Описание: | This is a multicenter, ambispective, low-interventional clinical study evaluating molecular genetic markers for non-invasive differential diagnosis of benign and malignant pigmented skin and mucosal neoplasms. In retrospective cohorts genetics markers will be identified. In prospective cohort non-invasive adhesive system will be tested to identify malignant or benign lesions with prespecified sensitivity and specificity compared to other non-invasive techniques (i.e. dermoscopy) and using histopathological examination as a "golden standard". |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | N/A |
| Начало: | 1 апреля 2020 г. |
| Окончание: | 1 ноября 2023 г. |
| Описание: | This is a multicenter, ambispective, low-interventional clinical study evaluating molecular genetic markers for non-invasive differential diagnosis of benign and malignant pigmented skin and mucosal neoplasms. In retrospective cohorts genetics markers will be identified. In prospective cohort non-invasive adhesive system will be tested to identify malignant or benign lesions with prespecified sensitivity and specificity compared to other non-invasive techniques (i.e. dermoscopy) and using histopathological examination as a "golden standard". |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | не указано |
| Начало: | 15 июня 2019 г. |
| Окончание: | 1 декабря 2023 г. |
| Описание: | This is a multicenter, non-interventional, retrospective study (with two prospective cohorts), including previously treated patients with melanoma, squamous cell lung cancer in the late stages (inoperable or metastatic) and Hodgkin disease at any stages. The duration of the follow-up will be 12-60 months. Data from medical records will be retrospectively collected at different points in time. The first data extraction will consist of collecting data from the initial level (before treatment with immune checkpoints inhibitors (anti-PD1 / PDl1) before the end of the recruitment period for this study (up to 3 years of follow-up). Two additional annual data collections are planned for display additional follow-up and data for patients who will survive. |
| смотреть на ClinicalTrials.gov |